Results

1–6 of 6 results for Ang-2

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Surrobody: Novel Platform With Strong Therapeutic Characteristics and a Lead Candidate Molecule Bispecific RO-634 to VEGF and Ang-2
On Demand Cases, Courses, and Papers
2022
Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020
Simultaneous Inhibition of Ang-2 and VEGF-A With Faricimab in DME: Additional Anatomical and Durability Outcomes From the BOULEVARD Phase 2 Trial
Vrinda S. Hershberger, MD, PhD
Annual Meeting Talks
2019